FDA updated Safety Communication: Ondansetron (Zofran) 32-mg, single IV dose pulled due to potential for serious cardiac risks


The 32-mg, single intravenous (IV) dose of the anti-nausea drug Zofran (ondansetron hydrochloride) will no longer be marketed because of the potential for serious cardiac risk, according to an updated Safety Communication from FDA.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.